# TRPM2 Channel Involvement in the Hesperidin-Mediated Potentiation of Cisplatin’s Antitumor Action in Laryngeal Carcinoma Cells

**Authors:** Ramazan Çınar, Kenan Yıldızhan, Halil İbrahim Altıner, Tarık Yağcı

PMC · DOI: 10.3390/ijms27031141 · International Journal of Molecular Sciences · 2026-01-23

## TL;DR

Hesperidin enhances cisplatin's effectiveness against laryngeal cancer by boosting TRPM2 activity, leading to increased cell death.

## Contribution

Identifies TRPM2 as a key mediator in hesperidin-enhanced cisplatin chemosensitivity in laryngeal carcinoma cells.

## Key findings

- Combined hesperidin and cisplatin reduced Hep-2 cell viability by 50%.
- TRPM2 protein expression increased with the combination treatment.
- TRPM2 inhibition reversed oxidative stress and mitochondrial dysfunction effects.

## Abstract

Cisplatin (CSP) is a first-line chemotherapeutic for laryngeal squamous cell carcinoma (LSCC), but its clinical effectiveness is limited by resistance and toxicity. Hesperidin (HESP), a citrus flavonoid, may enhance chemotherapeutic efficacy through pro-apoptotic properties. This study investigated the involvement of the transient receptor potential melastatin-2 (TRPM2) channel in the HESP-mediated potentiation of CSP-induced cytotoxicity in human laryngeal carcinoma (Hep-2) cells. Hep-2 cells were treated with CSP (25 µM), HESP (25 µM), or their combination for 24 h. The findings showed that the combined application of HESP and CSP reduced cell viability by approximately 50% (p < 0.001), which was the lowest compared to CSP alone. Western blot analysis revealed that TRPM2 protein expression was higher in the CSP+HESP group compared to the control group (p < 0.001). This synergistic treatment resulted in an increase in ROS production and a decrease in MDA levels, accompanied by a reduction in cellular GSH levels (p < 0.001). Furthermore, the combination therapy increased pro-inflammatory cytokines such as IL-1β and TNF-α (p < 0.001). Functional analyses showed that HESP treatment enhanced CSP-induced Ca2+ influx and altered mitochondrial membrane potential (p < 0.001). The pharmacological inhibition of TRPM2 with ACA and 2-APB reversed these effects, restoring redox balance and reducing cellular damage. In conclusion, HESP amplifies CSP-induced apoptosis in Hep-2 cells through TRPM2-dependent oxidative stress, Ca2+ dysregulation, and mitochondrial dysfunction. These findings identify TRPM2 as a mechanistic mediator of HESP-enhanced chemosensitivity in LSCC.

## Linked entities

- **Genes:** TRPM2 (transient receptor potential cation channel subfamily M member 2) [NCBI Gene 7226]
- **Proteins:** TRPM2 (transient receptor potential cation channel subfamily M member 2)
- **Chemicals:** cisplatin (PubChem CID 5460033), hesperidin (PubChem CID 10621), MDA (PubChem CID 1614), GSH (PubChem CID 124886), ACA (PubChem CID 1974), 2-APB (PubChem CID 1598)
- **Diseases:** laryngeal squamous cell carcinoma (MONDO:0005595), laryngeal carcinoma (MONDO:0002358)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TRPM2 (transient receptor potential cation channel subfamily M member 2) [NCBI Gene 7226] {aka EREG1, KNP3, LTRPC2, LTrpC-2, NUDT9H, NUDT9L1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}
- **Diseases:** inflammatory (MESH:D007249), cytotoxicity (MESH:D064420), mitochondrial dysfunction (MESH:D028361), Laryngeal Carcinoma (MESH:D007822), LSCC (MESH:D000077195)
- **Chemicals:** MDA (MESH:D015104), CSP (MESH:D002945), HESP (MESH:D006569), Ca2+ (-), 2-APB (MESH:C109986), GSH (MESH:D005978)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12897621/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12897621/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12897621/full.md

---
Source: https://tomesphere.com/paper/PMC12897621